retatrutide phase 2 results 2024 2025 Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Eli Lilly just announced striking

Subsequently, oral formulations and once weekly injections were developed in the 2010s and liraglutide was the first GLP-1 receptor agonist approved for the treatment of obesity in 2014

Current AOM coverage landscape and recent changes As of August 2024, Medicaid programs in 13 states covered at least one GLP-1 approved for weight management

KFF reports that policymakers and insurers are increasingly evaluating strategies to manage the financial impact of GLP-1 coverage, particularly within Medicare and Medicaid programs where long-term costs could become significant

the choice depends on your preference for injection frequency and dosing flexibility